Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors

James T. Palmer,* David Rasnick, Jeffrey L. Klaus, and Dieter Brömme

> Khepri Pharmaceuticals, Inc., 260 Littlefield Avenue, South San Francisco, California 94080

Received July 10, 1995

Proteases regulate a broad spectrum of physiological functions by the specific processing of proteins and peptides. Elevated levels of active proteases can result in an array of physiological processes ultimately leading to disease states. Therefore, compounds designed to restore the natural equilibrium of proteases present excellent opportunities for drug candidates.

Cysteine proteases, for example cathepsins B, L, and S, have been implicated in a number of diseases, including progressive cartilage and bone degradation associated with arthritis.¹ Inhibitors of these cathepsins have reduced inflammation and prevented joint destruction in animal models of arthritis.² Recently, human cathepsin O2 has been found to be highly expressed in osteoclastoma tissue.³ Cathepsins B and L have been linked to metastasis and invasion by cancer cells.⁴ The calcium-associated cysteine proteases calpains I and II have been associated with ischemia and hypoxia,⁵ Alzheimer's disease,⁶ and cataracts.⁷ Inhibition of the trypanosomal cysteine protease cruzain has proven effective in models of Chagas's disease.⁸

Reversible inhibitors of cysteine proteases include peptide aldehydes,⁹ nitriles,¹⁰ and α -ketocarbonyl compounds.¹¹ Irreversible inhibitors include peptide halomethyl ketones,¹² diazomethyl ketones,¹³ (acyloxy)methyl ketones,¹⁴ and ketomethylsulfonium salts,¹⁵ believed to alkylate the active site thiol by formal S_N2 displacement, either directly or through a proposed hemithioketal-episulfonium ion pathway. Other irreversible inhibitors include various epoxysuccinyl compounds,¹⁶ whose oxiranes are opened through nucleophilic attack by the thiol.

Previous work by Hanzlik and co-workers¹⁷ demonstrated peptide Michael acceptors as inactivators of the plant protease papain, which displayed second-order rate constants of inactivation from 0.05 to 70 M⁻¹ s⁻¹. However, to serve as disease modifying agents, inhibitors must inactivate target enzymes sufficiently *in vivo* as well as *in vitro*. Therefore, we designed potent inhibitors against *disease-associated* cysteine proteases such as the cathepsins B, L, S, and O2, calpains, and cruzain, concentrating on structures or scaffolds suitable for pharmaceutical development.

Molecular Design and Synthesis. Our approach required the catalytic mechanism of the targets to be vital for their inhibition. We designed inhibitors to be unreactive toward serine proteases, metalloproteases, and aspartyl proteases, nonactive site cysteines, and circulating thiols such as glutathione. We exploited a polarized yet inert double bond bearing functionality suitable for hydrogen bonding interactions with the active site of the target. The vinyl sulfone moiety (Figure 1) provided us with the necessary characteristics. Substituted vinyl sulfones are less reactive toward nucleophiles than the analogous vinyl ketones or esters¹⁸ and thus are sufficiently inert without the target. They also are capable of hydrogen bonding with the active site; at lower pH values (4.5-6.5) where cysteine proteases are most active, the active site His residue is protonated. Molecular modeling studies using the Discover program (Biosym) suggest the proposed interactions are valid.

Known substrate selectivity for cathepsins B, L, and S, calpains, and cruzain afforded us templates for our first-generation compounds.¹⁹ Although we recognized the potential loss of hydrogen bonding between active site elements and the carbonyl normally associated with protease substrates and enzyme-inhibitor transition states, we knew that the absence of a carbonyl group on papain inhibitors did not preclude time-dependent inactivation. Thus we constructed peptidomimetic structures containing "functional scaffolds" enabling both inhibitor-protease binding and mechanistic inactivation.

We required a versatile, stereospecific, and scaleable synthesis scheme with minimal purification steps. Chiral amino acid aldehydes, as reported by Fehrentz and Castro,²⁰ afforded us suitable building blocks. Reduction of N,O-dimethylhydroxamates 2 derived from commercially available α -amino acids 1 gave the requisite aldehydes 3 in excellent yields (Scheme 1). Wadsworth-Emmons²¹ chemistry provided the vinyl sulfones 5 in good to excellent yields, with little or no chromatography needed. Removal of the BOC groups followed. Mixed anhydride coupling of the amine salts 6 with N-protected amino acids or peptide derivatives 7 gave the target peptidomimetic vinyl sulfones 8. NMR spectroscopy confirmed the absence of possible aldehyde contamination in the vinyl sulfones, eliminating possible interference from aldehydes in the inhibition assays.

For our first series of enzyme kinetics, we assayed several compounds in time-based inactivation assays against cathepsins B, L, S, and O2, cruzain, and calpains I and II. The most potent inhibitors against cathepsin S displayed second-order rate constants approaching the diffusion limit.

Using this family of inhibitors, it became apparent that cathepsin S is the most readily inactivated enzyme, followed by cathepsin L and cathepsin O2, and then cathepsin B. Cruzain is homologous to cathepsin $L;^{23}$ we used the X-ray structure of cruzain to model inhibitors for cathepsin L. As anticipated, both enzymes show similar susceptibility to the inhibitors.

The calpains are decidedly resistant to most inhibitors in this series. Nevertheless, the incorporation of known binding determinants for calpain (Leu-Leu-Tyr or Leu-Leu-Met) into a series of vinyl sulfones resulted in significant inactivation (entries 8i-m.)

Scope and Limitations. As stated earlier, the potential utility of this series of compounds depends on a number of factors, including (a) selectivity for cysteine proteases, (b) stability of target enzyme inactivation, and (c) their chemical stability, including that toward circulating thiols such as glutathione (GSH). To test this series of requirements, we performed the following experiments.

MeOSuc-Ala-Ala-Pro-ValVSPh, a vinyl sulfone derivative designed with specificity for human leukocyte elastase, was incubated with HLE in the presence of



Figure 1.





^a R₁, R₂ = amino acid side chain; R" = alkyl or aryl; X = Cl or p-CH₃C₆H₄SO₃⁻; PG = N-terminus protecting group. Reaction conditions: (a) HCl-HN(CH₃)OCH₃, DCC, Et₃N, CH₂Cl₂, 0-25 °C; (b) LiAlH₄, THF, 0 °C; (c) NaH, THF, 0-25 °C; (d) HCl/dioxane or p-TsOH/ether; (e) 4-methylmorpholine, isobutyl chloroformate, THF, -10 °C. **8a**-m: **8a** = Mu-Phe-HphVSMe; **8b** = Mu-Phe-HphVSPh;²² **8c** = Mu-Tyr(3,5-I₂)-HphVSPh; **8d** = Mu-Phe-LysVSPh.HBr; **8e** = Mu-Leu-HphVSPh; **8f** = Mu-Np2-HphVS-2Np; **8g** = Mu-Phe-HphVSEtPh; **8h** = Mu-2Np-HphVSEtPh; **8i** = Ac-Leu-Leu-MetVSPh; **8j** = Ac-Leu-Leu-NleVSPh; **8k** = Mu-Leu-LyrVSPh; **8l** = Ac-Leu-Leu-Met(O₂)VSPh; **8m** = Z-Leu-Leu-TyrVSPh. Abbreviations: Mu = morpholine urea, Z = benzyloxycarbonyl, Ac = acetyl. Where an amino acid abbreviation is used in reference to an R₂ or R₁ residue, it signifies the side chain portion of that amino acid. For example, "Hph" at R₁ = homophenylalanine side chain, CH₂CH₂C₆H₅; Mu-Phe at R₂ = morpholine urea of phenylalanine. Others: Np2 = 2-naphthylalanine, Tyr(3,5-I₂) = 3,5-diiodotyrosine, Nle = norleucine, Met(O₂) = methionine sulfone, VSMe = (vinylsulfonyl)methane, VSPh = (vinylsulfonyl)-2-naphthalene, VSEtPh = [(vinylsulfonyl)ethyl]benzene.

Table 1. Vinyl Sulfone Inhibition Kinetics $(k_{obs}/[I], M^{-1} s^{-1})$

| entry | cathepsin B | cathepsin L | cathepsin S | cathepsin O2 | cruzain | calpain I,* calpain II |
|----------------------------|--|---|---|---------------------------------|--|----------------------------------|
| 8a 8d 8g 8h 8i | $5\ 100\ 11\ 300\ 29\ 000\ 33\ 000\ 0$ | $\begin{array}{r} 8\ 700\\ 220\ 000\\ 340\ 000\\ 2\ 240\ 000\\ 880\ 000\end{array}$ | $\begin{array}{c}1\ 200\ 000\\10\ 700\ 000\\4\ 700\ 000\\29\ 000\ 000\end{array}$ | 6540 83300 28500 25000 | $\begin{array}{c} 22\ 000\\ 149\ 000\\ 180\ 000\\ 450\ 000\\ 110\ 000 \end{array}$ | 0 |
| 8j | 0 | 930 000 | | 20 000 | 133 000 | 6 900* 7 200* |
| 8k | | 28 700 | $25\ 100$ | 815 | | 10 800** |
| 81 | 0 | $1\ 500\ 000$ | | $22\ 700$ | $104\ 000$ | 8 400* |
| 8m | 730 | | 280 000 | 900 | $45\ 000$ | $24 \ 300^{*}$ $6 \ 400^{**}$ |

100 mM Tris (pH 7.5). This compound neither inhibited nor bound to the enzyme, suggesting that the vinyl sulfone series was indeed specific for cysteine proteases over serine proteases.

To explore the irreversibility of cysteine protease inactivation by this series, we performed the following. Cathepsin B was completely inactivated with Mu-Phe-HphVSPh under optimal conditions (50 mM phosphate, pH 6.0, 2.5 mM EDTA, 2.5 mM dithiothreitol (DTT). The inactivated enzyme was passed twice through a G-25 column and eluted with assay buffer to remove excess inhibitor. There was no recovery of enzymatic activity against the substrate when periodically assayed over the next 4 days. Control cathepsin B (treated similarly but without inhibitor) retained 37% of its activity during this period.

An examination of chemical stability of the various derivatives demanded a more rigorous kinetic analysis to compare the components of the second-order rate equation. Progress curves were computer-fit to a first-order equation to produce k_{obs} as previously described.²⁴ Kinetic constants for compounds listed in Table 1 are reported as $k_{obs}/[I]$, whereby the k_{obs} values were determined from at least six inhibitor concentrations near K_i (for example, against cathepsin S, the concentrations of compound **8b** ranged from 1 to 20 nM of inhibitor, those of compound **8f** ranged from 1 to 10 nM) and fitted to the equation

$$k_{
m obs} = rac{k_{
m irr}[{
m I}]}{K_{
m i app} + [{
m I}]}$$

where $K_{i \text{ app}}$ is the apparent K_i value, k_{irr} is the calculated first-order inactivation constant, and [I] is the inhibitor concentration. Since the inhibition was measured in the presence of substrate, the true K_i was

Table 2. Detailed Inhibition Kinetics

| compound | $k_{\rm irr}^a$ or $k_{\rm inact}$ (s ⁻¹) | $K_{ m i}$ ($\mu m M$) | $(k_{\text{irr}^a} \text{ or } k_{\text{inact}})/K_i (M^{-1} \text{ s}^{-1})$ | | | | |
|-------------------------------|---|---------------------------|---|--|--|--|--|
| Cathepsin B | | | | | | | |
| Mu-Phe-HphVSPh (8b) | 0.17 ± 0.04 | 11 ± 3.5 | $16\;400\pm1300$ | | | | |
| $Mu-Tyr(3,5-I_2)-HphVSPh(8c)$ | 0.36 ± 0.01 | 0.34 ± 0.02 | $1\ 080\ 000\pm 40\ 000$ | | | | |
| Mu-Leu-HphVSPh (8e) | 0.17 ± 0.06 | 39 ± 13 | $4~250\pm71$ | | | | |
| Mu-Np2-HphVS-2Np (8f) | 0.061 ± 0.006 | 0.15 ± 0.02 | $420\ 000\pm 20\ 000$ | | | | |
| Cathepsin L | | | | | | | |
| Mu-Phe-HphVSPh (8b) | 0.24 ± 0.08 | 1.0 ± 0.3 | $224\ 000\pm 30\ 000$ | | | | |
| Mu-Leu-HphVSPh (8e) | 0.28 ± 0.15 | 0.72 ± 0.40 | $387\ 000\pm 4\ 000$ | | | | |
| Mu-Np2-HphVS-2Np (8f) | 0.14 ± 0.03 | 0.018 ± 0.006 | $9\ 200\ 000\ \pm\ 500\ 000$ | | | | |
| Cathepsin S | | | | | | | |
| Mu-Phe-HphVSPh (8b) | 0.085 ± 0.021 | 0.011 ± 0.003 | $7 \; 700 \; 000 \pm 200 \; 000$ | | | | |
| Mu-Leu-HphVSPh (8e) | 0.16 ± 0.01 | 0.0059 ± 0.0004 | $26\;300\;000\pm500\;000$ | | | | |
| Mu-Np2-HphVS-2Np (8f) | 0.10 ± 0.02 | 0.0018 ± 0.0004 | $56\ 000\ 000\ \pm\ 8\ 000\ 000$ | | | | |
| Cathepsin O2 | | | | | | | |
| Mu-Phe-HphVSPh (8b) | 0.31 ± 0.07 | 30.5 ± 9.7 | 10 164 | | | | |
| Mu-Leu-HphVSPh (8e) | 0.17 ± 0.05 | 0.23 ± 0.10 | 772 700 | | | | |
| Mu-Np2-HphVS-2Np (8f) | | | $<300 \; (k_{\rm obs}/[I])$ | | | | |
| Cruzain | | | | | | | |
| Mu-Phe-HphVSPh (8b) | 0.072 ± 0.028 | 0.36 ± 0.018 | $203\ 000\pm 23\ 000$ | | | | |
| Mu-Leu-HphVSPh (8e) | 0.13 ± 0.07 | 0.22 ± 0.13 | $620\ 000 \pm 40\ 000$ | | | | |
| Mu-Np2-HphVS-2Np (8f) | 0.046 ± 0.003 | 0.048 ± 0.01 | $1\ 040\ 000\ \pm\ 10\ 000$ | | | | |

^{*a*} k_{irr} for cathepsin B only.

determined by the relationship

$$K_{\rm i} = \frac{K_{\rm i \ app}}{1 + [S]/K_{\rm m}}$$

The second-order rate constant $k_{\rm irr}/K_{\rm i}$ was independently determined from the slope of the plot of $1/k_{obs}$ vs 1/[I] and compared to that computed from the ratio of $k_{\rm irr}$ and $K_{\rm i}$.²⁵ Results comparing inhibition of the target enzymes by several vinyl sulfones are depicted in Table 2. The sulfonyl moiety clearly plays a significant role in binding. Enhanced hydrophobicity in progressing from the phenyl to the 2-naphthyl series (8b, 8f) may explain these results.

Variability between compounds for a particular enzyme is clearly controlled by the degree of binding to the enzyme. Inactivation of the cysteine proteases by the inhibitors was performed in the presence of substrate, which slowed down the inactivation sufficiently to allow reliable measurement of rates. For example, while the first order rate constant k_{irr} varies only slightly across the entire series of enzymes, the K_i values range from mid-micromolar to low nanomolar. This suggests the electrophilicity of the vinyl sulfone moiety is of less importance to the enzyme's inactivation than are the vital hydrophobic interactions.

To test this idea further, we measured the stability of selected inhibitors toward glutathione (GSH) using the method described by Shaw and co-workers.²⁶ After incubation with GSH (2.5 mM) in the cathepsin S assay buffer at pH 6.2, Mu-Phe-HphVSPh (**8b**, 10μ M) lost no inhibitory potency after 22 h incubation. Similarly, the second-order rate constant for the loss of GSH was 5.5 \times 10⁻⁴ M⁻¹ s⁻¹ for Mu-Phe-LysVSPh·HBr (8d). Given the second-order inhibition constants for these and similar compounds against the target enzymes are at least 10⁷ times greater, one may reasonably assume that peptide-based vinyl sulfones are effectively inert in the absence of the enzymes' catalytic machinery. As such, they represent a novel class of therapeutic candidates that may be employed against those diseases manifested by the upregulation of these proteases. At the same

time, their specificity and stability may alleviate many of the traditional concerns associated with potentially toxic, mutagenic, non-enzyme-selective, or highly reactive substituted methyl ketones and epoxides previously reported.

References

- (1) (a) Maciewicz, R. A.; Wotton, S. F.; Etherington, D. J.; Duance, V. C. Susceptibility of the Cartilage Collagens Types II, IX and XI to Degradation by the Cysteine Proteases, Cathepsins B and L. FEBS Lett. 1990, 269, 189–93. (b) Page, A. E.; Hayman, A. E.; Andersson, L. M. B.; Chambers, T. J.; Warburton, M. J. Degradation of Bone Matrix Proteins by Osteoclast Cathepsins.
- (a) Esser, R. E.; Angelo, R. A.; Murphey, M. D.; Watts, L. M.; Thornburg, L. P.; Palmer, J. T.; Talhouk, J. W.; Smith, R. E. Cysteine Proteinase Inhibitors Decrease Articular Cartilage and Bone Destruction in Chronic Inflammatory Arthritis. Arthritis Rheumatism 1994, 37, 236–247. (b) Esser, R. E.; Watts, L. M.; Angelo, R. A.; Thornburg, L. P.; Prior, J. J.; Palmer, J. T. The Effects of Fluoromethyl Ketone Inhibitors of Cathepsin B on Adjuvant Induced Arthritis. J. Rheumatol. **1993**, 20, 1176–1183. (c) Ahmed, N. K.; Martin, L. A.; Watts, L. M.; Palmer, J.; Thornburg, L.; Prior, J.; Esser, R. Peptidyl Fluoromethyl Ketones as Inhibitors of Cathepsin B: Implication for Treatment of Rheumatoid Arthritis. Biochem. Pharmacol. 1993, 44, 1201-1207.
- (3) Brömme, D.; Okamoto, K. Human Cathepsin O2, a Novel Cysteine Protease Highly Expressed in Osteoclastomas and Ovary. Molecular Cloning, Sequencing, and Tissue Distribution. Biol. Chem. Hoppe-Seyler **1995**, 376, 379–384.
- (4) Duffy, M. J. The Role of Proteolytic Enzymes in Cancer Invasion and Metastasis. *Clin. Exp. Metastasis* 1992, 10, 145-155.
 (5) (a) Seubert, P.; Lee, K.; Lynch, G. Ischemia Triggers NMDA Receptor-Linked Cytoskeletal Proteolysis in Hippocampus. *Brain* Res. 1989, 492, 366–370. (b) Arai, A.; Kessler, M.; Lee, K.; Lynch, G. Calpain Inhibitors Improve the Recovery of Synaptic Transmission from Hypoxia In Hippocampus Slices. Brain Res. 1990, 532, 63-68.
- (6) Saito, K.; Elce, J. S.; Hamos, J. E.; Nixon, R. A. Widespread Activation of Calcium-Activated Neutral Proteinase (Calpain) in the Brain in Alzheimer's Disease: A Potential Molecular Basis of Neuronal Degeneration. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2628-2632.
- (7) David, L. L.; Shearer, T. R.; Shih, M. Sequence Analysis of Lens β-Crystallins Suggests Involvement of Calpain in Cataract
- Formation. J. Biol. Chem. 1993, 268, 1937-1940. Ashall, F.; Angliker, H.; Shaw, E. Lysis of Trypanosomes by Peptidyl Fluoromethyl Ketones. Biochem. Biophys. Res. Com-
- mun. 1991, 170, 923–929 (9) Hanzlik, R. P.; Jacober, S. P.; Zygmunt, J. Reversible Binding of Peptide Aldehydes to Papain. Structure-Activity Relationships. Biochim. Biophys. Acta 1991, 1073, 33-42.
- Hanzlik, R. P.; Zygmunt, J.; Moon, J. B. Reversible Covalent Binding of Peptide Nitriles to Papain. *Biochim. Biophys. Acta* 1990, 1035, 62-70.

- (11) (a) Angelastro, M. R.; Mehdi, S.; Burkhart, J. P.; Peet, N. P.; Bey, P. α-Diketones and α-Keto Ester Derivatives of N-Protected Amino Acids and Peptides as Novel Inhibitors of Cysteine and Serine Proteinases. J. Med. Chem. 1990, 33, 11-13. (b) Hu, L.-Y.; Abeles, R. H. Inhibition of Cathepsin B and Papain by Peptidyl α-Keto Esters, α-Keto Amides, α-Diketones, and α-Keto Acids. Arch. Biochem. Biophys. 1990, 281, 271-274. (c) Li, Z.; Patel, G. S.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T.; Powers, J. C. Peptide α-Keto Ester, α-Keto Amide, and α-Keto Acid Inhibitors of Calpains and Other Cysteine Proteases. J. Med. Chem. 1993, 36, 3472-3480. (d) Harbeson, S. L.; Abelleira, S. M.; Akiyama, A.; Barrett, R., III; Carroll, R. M.; Straub, J. A.; Tkacz, J. N.; Wu, C.; Musso, G. F. Stereospecific Synthesis of Peptidyl α-Keto Amides as Inhibitors of Calpain. J. Med. Chem. 1994, 37, 2918-2829.
- (12) Rasnick, D. Synthesis of Peptide Fluoromethyl Ketones and the Inhibition of Human Cathepsin B. Anal. Biochem. 1985, 149, 461-465.
- (13) Crawford, C.; Mason, R. W.; Wikstrom, P.; Shaw, E. The Design of Peptidyldiazomethane Inhibitors to Distinguish Between the Cysteine Proteinases Calpain II, Cathepsin L, and Cathepsin B. Biochem. J. 1988, 253, 751.
- Cysteine Proteinases Carpain II, Cattepsin I, and Cattepsin B. Biochem. J. 1988, 253, 751.
 (14) Smith, R. A.; Copp, L. J.; Coles, P. J.; Pauls, H. W.; Robinson, V. J.; Spencer, R. W.; Heard, S. B.; Krantz, A. New Inhibitors of Cysteine Proteinases. Peptidyl Acyloxymethyl Ketones and the Quiescent Nucleofuge Strategy. J. Am. Chem. Soc. 1988, 110, 4429-4431.
- (15) Shaw, E. Peptidyl Sulfonium Salts: A New Class of Protease Inhibitors. J. Biol. Chem. 1988, 263, 2768-2772.
- (16) See, for example: Gour-Joso, 205, 2160 2112.
 (16) See, for example: Gour-Salin, B. J.; Lachance, P.; Bonneau, P. R.; Storer, A. C.; Kirschke, H.; Brömme, D. E-64 Analogs as Inhibitors of Cathepsin L and Cathepsin S: Importance of the S₂-P₂ Interactions for Potency and Selectivity. *Bioorg. Chem.* 1994, 22, 227-241.
- (17) (a) Hanzlik, R. P.; Thompson, S. A. Vinylogous Amino Acid Esters: A New Class of Inactivators for Thiol Proteases. J. Med. Chem. 1984, 27, 711-712. (b) Thompson, S. A.; Andrews, P. R.; Hanzlik, R. P. Carboxyl-Modified Amino Acids and Peptides as Protease Inhibitors. J. Med. Chem. 1986, 29, 104-111. (c) Liu, S.; Hanzlik, R. P. Structure-Activity Relationships for Inhibition of Papain by Peptide Michael Acceptors. J. Med. Chem. 1992, 35, 1067-1075.
- (18) For recent reviews of vinyl sulfone chemistry, see: (a) Simpkins, N. S. The Chemistry of Vinyl Sulfones. *Tetrahedron* **1990**, 46, 6951-6984. (b) Fuchs, P. L.; Braish, T. F. Multiply Convergent Syntheses Via Conjugate-Addition Reactions to Cycloalkenyl Sulfones. *Chem. Rev.* **1986**, 86, 903-918.
- (19) See, for example, Shaw, E. Cysteine Proteinases and Their Selective Inactivation. Adv. Enzymol. Relat. Areas Mol. Biol. 1990, 63, 271 and references cited therein.
- (20) Fehrentz, J. A.; Castro, B. An Efficient Synthesis of Optically Active α-(t-butoxycarbonylamino)-Aldehydes from α-Amino Acids. Synthesis 1983, 676.
- (21) Wadsworth, W. S. Synthetic applications of phosphoryl-stabilized anions. Org. React. **1977**, 25, 73-250.

- (22) Mp: 143-144 °C. TLC (50% ethyl acetate/CH₂Cl₂): $R_f = 0.45$. ¹H NMR (CDCl₃): δ 1.68-1.93 (2H, m, CH₂CH₂C₆H₅), 2.58 (2H, CH₂CH₂C₆H₅), 3.03 (2H, d, J = 7 Hz, PhCH₂CH₂O), 3.27 (4H, m, 2 × NCH₂CH₂O), 3.62 (4H, m, 2 × NCH₂CH₂O), 4.44 (1H, q, J= 7 Hz, CHNH (Phe)), 4.62 (1H, m, CHNH (Hph)), 4.93 (1H, d, J = 7 Hz, NHCH (urea)), 6.08 (1H, dd, J = 2, 15 Hz, trans SO₂CH=CH), 6.23 (1H, d, J = 7 Hz, NHCH (amide)), 6.77 (1H, dd, J = 5, 15 Hz, trans CH=CHSO₂), 7.07-7.87 (15H, m, aromatic). MS (fast-atom bombardment, high resolution): calculated for C₃₁H₃₅N₃O₅S, (m + H) 562.2376, found 562.2362. Anal. Calcd for C₃₁H₃₄N₃N₃O₅S: C, 66.29%; H, 6.10; N, 7.48; S, 5.70. Found: C, 66.03; H, 6.45; N, 7.45; S, 5.83.
- (23) Eakin, A. E.; Mills, A. A.; Harth, G.; McKerrow, J. H.; Craik, C. S. The Sequence, Organization, and Expression of the Major Cysteine Protease (Cruzain) from *Trypanosoma cruzi*. J. Biol. Chem. **1992**, 267, 7411-7420.
- (24) (a) Tian, W.-X; Tsou, C.-L. Determination of the Rate Constants of Enzyme Modifications by Measuring the Substrate Reaction in Presence of the Modifier. *Biochemistry* 1982, 21, 1028-1032.
 (b) Brömme, D.; Schierhorn, A.; Kirschke, H.; Wiederanders, B.; Barth, A.; Fittkau, S.; Demuth, H.-U. Potent and Selective Inactivation of Cysteine Proteinases with N-Peptidyl-O-Acyl Hydroxylamines. *Biochem. J.* 1989, 263, 861-866.
- (25) Conditions for cathepsin B assays were as follows: 50 mM phosphate, pH 6.0, 2.5 mM EDTA, 2.5 mM dithiothreitol (DTT), 50 μ M substrate (Z-Arg-Arg-AMC; K_m = 190 μ M). Conditions for cathepsin L assays were as follows: 50 mM acetate, pH 5.5, 2.5 mM EDTA, 2.5 mM DTT, 5 μ M substrate (Z-Phe-Arg-AMC; $K_{\rm m} = 2 \ \mu {\rm M}$). Conditions for cathepsin S assays were as follows: $M_{\rm m} = 2 \,\mu{\rm M}$, contains for carbon being and a start of the s cathespin O2 assays were the same as for cathepsin S with the exception of the substrate used was Z-Phe-Arg-AMC, $K_{\rm m} = 4.5$ μ M. Conditions for cruzain assays were the same as for cathepsin L with the exception that the substrate $K_{\rm m}$ was 1 μ M. The conditions for the calpain assays were as follows: 50 mM Tris, pH 7.5, 5 mM Ca²⁺, 2.5 mM DTT, 50 μM substrate (Suc-Leu-Tyr-AMC; K_m (calpain I) = 1.1 mM, K_m (calpain II) = 2.6 mM). The concentration of DMF in all assays was <1%. In the presence of substrate and inhibitor, the assay at 25 °C was started by the addition of enzyme (final concentrations approximately 5-10, 1-5, 0.03-0.01, 1-5, and 20 nM for cathepsins B, L, and S, cruzain, and the calpains, respectively). A Perkin-Elmer fluorimeter was used to measure the increase in fluorescence at 450 nm with excitation at 380 nm for 5 min or until the enzyme activity was reduced to 1% or less. Without inhibitor, the assay was linear throughout the range observed. Duplicate runs were measured.
- (26) Angliker, H.; Wikstrom, P. Rauber, P.; Shaw, E., The Synthesis of Lysylfluoromethanes and Their Properties as Inhibitors of Trypson, Plasmin, and Cathepsin B. *Biochem. J.* 1987, 241, 871-875.

JM950500G